Migraine relief can mean less head pain, but it can also mean being free of the nausea or sensitivity that makes an attack difficult to manage. A trial published in Headache tested both. Adults who used a vaporised mixture containing THC and CBD were more likely to report pain relief, no pain, and freedom from their most bothersome symptom two hours later than after placebo.
The result was specific to the mixture. CBD-dominant cannabis did not outperform placebo on those outcomes. The published study by Schuster and colleagues therefore answers a question about defined cannabis flower preparations, rather than demonstrating a benefit from CBD oil. This summary is based on the published abstract.
Why the trial measured more than headache pain
The NHS description of migraine includes nausea and sensitivity to light and sound alongside a potentially severe headache. For someone living with migraine, a treatment's effect on these accompanying symptoms can matter as much as a change in a pain score.
The researchers separated pain relief from pain freedom. Relief means the pain improved; freedom means no pain remained at the assessment. They also asked about freedom from the most bothersome symptom. These are different outcomes, and the trial's results varied between them.
Four preparations, separate attacks
The randomised trial enrolled 92 adults with migraine. Participants treated up to four separate attacks, receiving the preparations in a randomly assigned order. Across the trial, 247 attacks were treated.
The four treatments were vaporised cannabis flower containing 6% THC, flower containing 11% CBD, a combination containing 6% THC plus 11% CBD, and placebo flower. THC and CBD are different cannabinoids, compounds found in cannabis. The percentages describe the preparations used in this research, not recommended amounts for readers.
This was a crossover trial: participants could receive each treatment across different attacks. It was also double-blind and placebo-controlled, meaning neither participants nor researchers were meant to know which preparation was being used, and an inactive comparison was included. At least one week separated treated attacks. The main assessment took place two hours after vaporisation.
What changed after two hours
With the THC-and-CBD combination, the authors reported pain relief in 67.2% of assessments, compared with 46.6% after placebo. Pain freedom was reported in 34.5% versus 15.5%. Freedom from the most bothersome symptom was reported in 60.3% versus 34.5%. All three comparisons favoured the combination and were statistically significant.
The combination also improved sustained pain freedom at 24 hours and sustained freedom from the most bothersome symptom at 24 and 48 hours. The abstract does not give the corresponding percentages, so those longer-lasting findings cannot be described as a specific extra number of symptom-free hours.
THC-dominant flower improved pain relief compared with placebo, with reported rates of 68.9% and 46.6%. It did not show superiority for pain freedom or freedom from the most bothersome symptom at two hours. CBD-dominant flower did not show superiority over placebo for any of these three two-hour outcomes.
What this means for the CBD question
The trial provides an encouraging result for the particular THC-and-CBD preparation tested during acute migraine attacks. It also gives a clear reason to keep cannabis and CBD findings separate. The presence of CBD in the successful mixture does not establish that CBD alone produced the benefit.
The comparisons described in the abstract were against placebo. They do not establish that the combination was better than an established migraine medicine, or that adding CBD was better than THC alone. Nor was this a study of preventing future attacks.
No serious adverse events were reported. That statement does not mean there were no side effects, and the abstract does not provide a detailed account of non-serious events. The findings concern vaporised flower, so they do not demonstrate the same effects from an oral oil or another route.
Where the result leaves people with migraine
This study makes the formulation question more concrete: a defined THC-and-CBD mixture improved several attack outcomes compared with placebo, while CBD-dominant flower did not. For readers interested in CBD, the useful takeaway is to check exactly what a migraine study tested before treating its headline as evidence for a different preparation.
The NHS distinguishes treatments for an attack from treatments intended to prevent attacks. This trial belongs to the first question. It adds a published finding about acute symptoms, without establishing a replacement for an individual's migraine treatment plan.
